We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cepheid (CPHD) Gets FDA Clearance for Xpert TV Assay
Read MoreHide Full Article
Cepheid recently received an approval for its Xpert TV assay from the U.S. FDA. Notably, Xpert TV is a urine-based test that uses the Nucleic Acid Amplification Testing (NAAT) procedure for detection of Trichomonas vaginalis, a non-viral sexually transmitted infection in men.
A thorough analysis reveals that the current market sentiments are quite unimpressive for Cepheid as it represents a modest one-year return of 1.3%, much lower than the S&P’s return of 10.1% over the same time frame. We believe that the recent development will to-some-extent help the company overcome the unfavorable situation.
Meanwhile, we note that Xpert TV had previously received an initial clearance for three types of female specimen in Oct 2015. The latest advancement not only extends the usage of the assay but also delivers rapid test-results in as less as 35 minutes. The company would initiate shipping of the newly modified version of Xpert TV later this month.
As per management, the approval will fortify Cepheid’s market position as it adds to the company’s flagship GeneXpert System. Notably, the platform has 20 Xpert tests in the U.S. and more than 11,000 systems installed globally.
The molecular diagnostic market, with infectious diseases as an important platform is expected to reach a worth of $9,333.8 million by 2020, growing at a CAGR of 9.3%, as per Markets and Markets. Buoyed by such bullish trends, we believe that Cepheid is poised to gain from the latest development.
Zacks Rank and Other Key Picks
Currently, Cepheid has a Zacks Rank #2 (Buy).
Other favorably ranked stocks in the broader medical sector include CryoLife Inc. , Masimo Corporation (MASI - Free Report) and IDEXX Laboratories Inc. (IDXX - Free Report) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cepheid (CPHD) Gets FDA Clearance for Xpert TV Assay
Cepheid recently received an approval for its Xpert TV assay from the U.S. FDA. Notably, Xpert TV is a urine-based test that uses the Nucleic Acid Amplification Testing (NAAT) procedure for detection of Trichomonas vaginalis, a non-viral sexually transmitted infection in men.
A thorough analysis reveals that the current market sentiments are quite unimpressive for Cepheid as it represents a modest one-year return of 1.3%, much lower than the S&P’s return of 10.1% over the same time frame. We believe that the recent development will to-some-extent help the company overcome the unfavorable situation.
Meanwhile, we note that Xpert TV had previously received an initial clearance for three types of female specimen in Oct 2015. The latest advancement not only extends the usage of the assay but also delivers rapid test-results in as less as 35 minutes. The company would initiate shipping of the newly modified version of Xpert TV later this month.
As per management, the approval will fortify Cepheid’s market position as it adds to the company’s flagship GeneXpert System. Notably, the platform has 20 Xpert tests in the U.S. and more than 11,000 systems installed globally.
CEPHEID INC Price
CEPHEID INC Price | CEPHEID INC Quote
Our Take
The molecular diagnostic market, with infectious diseases as an important platform is expected to reach a worth of $9,333.8 million by 2020, growing at a CAGR of 9.3%, as per Markets and Markets. Buoyed by such bullish trends, we believe that Cepheid is poised to gain from the latest development.
Zacks Rank and Other Key Picks
Currently, Cepheid has a Zacks Rank #2 (Buy).
Other favorably ranked stocks in the broader medical sector include CryoLife Inc. , Masimo Corporation (MASI - Free Report) and IDEXX Laboratories Inc. (IDXX - Free Report) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>